

## Republic of the Philippines Department of Health

## Food And Drug Administration



Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa

City

City

## **Notification of Cosmetic Product**

Pursuant to the existing rules and regulations of the Food and Drug Administration (FDA) for the notification of cosmetics, the product notification is hereby acknowledged,

Cosmetic Notification Number: NN-1000006067336

Validity: 17 March 2023

**Particulars of the Product** 

Brand Name: DANDREX

Product Name: DANDREX ANTI-DANDRUFF SHAMPOO

Variant/s: N/A

Particulars of the Manufacturer

Name of the Manufacturer: ARB LABORATORIES INC.

Address of the Manufacturer: Lot # 15 North Zuzuaregui St., Old Balara, Quezon City, Metro

Manila

Country of Manufacture: Philippines

Particulars of the Local Company Responsible for Placing the Product in the Market

Name of the Company: ESKEEN LABORATORIES INC.

UG1 Star Centrum Condominiums, Gil Puyat Avenue corner

Address of the Company: Malugay Stret, Barangay Bel-Air, Makati, Makati, Metro

Manila, 1209

LTO Number: LTO-3000001771311

The product is allowed to be sold in the local market subject to compliance with the requirements of the ASEAN Cosmetic Directive and the FDA laws, and its implementing rules and regulations. This notification should not be taken as a guarantee and/or endorsement of the safety, quality, and claimed benefit of the product. Any subsequent changes to the information submitted in this notification will render this notification invalid and a new notification will have to be submitted.

The company hereby ensures that they shall respond and cooperate fully with the FDA with regard to any subsequent post-marketing activity initiated by the FDA. Further, the company shall be responsible for ensuring that each consignment of the product continues to meet all the legal requirements, and conforms to all the standards and specifications of the product declared to the FDA.

This authorization is subject to suspension, cancellation, or recall should any violation of FDA laws, and its implementing rules and regulations, involving the product be committed.

BY AUTHORITY OF THE ACTING DIRECTOR GENERAL

Engr. Ana Trinidad F. Rivera, MSc
Director IV, Center for Cosmetic Regulation and Research